Company Encyclopedia
View More
name
Metagenomi
MGX.US
Metagenomi, Inc., a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. Its genome editing toolbox includes nuclease-based genome editing, base editors, RNA-mediated integration, including prime editing, and DNA-mediated integration, such CRISPR-associated transposases. The company has a collaboration and license agreement with Ionis Pharmaceuticals, Inc. to research, develop and commercialize investigational medicines using genome editing technologies; and a development, option, and license agreement with Affini-T Therapeutics, Inc.
1.907 T
MGX.USMarket value -Rank by Market Cap -/-

Financial Score

22/11/2025 Update
D
BiotechnologyIndustry
Industry Ranking290/394
Industry medianC
Industry averageD
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreE
    • ROE-40.87%E
    • Profit Margin-287.06%E
    • Gross Margin-191.99%E
  • Growth ScoreE
    • Revenue YoY-43.88%E
    • Net Profit YoY-19.99%D
    • Total Assets YoY-30.81%E
    • Net Assets YoY-30.23%E
  • Cash ScoreE
    • Cash Flow Margin-34.84%D
    • OCF YoY-43.88%E
  • Operating ScoreE
    • Turnover0.1E
  • Debt ScoreB
    • Gearing Ratio28.03%B

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Metagenomi Inc. to Present at Jefferies Global Healthcare Conference in London

    Metagenomi Inc. will present at the Jefferies Global Healthcare Conference in London on November 20, 2025. CEO Jian Irish will deliver the presentation, and a live webcast will be available on the company’s investor website.

    Reuters·
    US
    MGX
    0.00%
    Reuters·
    US
    MGX
    0.00%

    Metagenomi, Inc. Reports Q3 2025 Financial Results

    Metagenomi, Inc. (MGX) reported its Q3 2025 financial results, showing a net loss of $20.4 million, up from $18.8 million a year prior. Revenue from collaborations fell to $8.7 million from $11.5 million, while operating expenses decreased to $31.5 million. The company holds $32.8 million in cash and $151.3 million in marketable securities. R&D expenses were $25.3 million as Metagenomi focuses on advancing its genetic medicine programs and genome editing technology for future growth.

    Tip Ranks·
    US
    MGX
    0.00%
    Tip Ranks·
    US
    MGX
    0.00%

    Chardan Capital Keeps Their Buy Rating on Metagenomi, Inc. (MGX)

    Chardan Capital analyst Geulah Livshits has maintained a Buy rating on Metagenomi, Inc. (MGX) with a price target of $7.00. Livshits, who focuses on the Healthcare sector, has an average return of 22.2% and a 41.55% success rate on recommended stocks. Additionally, TD Cowen's Joseph Thome also issued a Buy rating for Metagenomi, while TR | OpenAI reiterated a Hold rating on November 8.

    Tip Ranks·
    US
    MGX
    0.00%
    Tip Ranks·
    US
    MGX
    0.00%

    Metagenomi Announces Positive Preclinical Data for MGX-001

    Metagenomi, Inc. announced positive preclinical data for its MGX-001 hemophilia A program, showing curative FVIII activity in non-human primates. The company is prioritizing this program while reducing its workforce by 25% to extend its cash runway into Q4 2027. Jian Irish has been appointed as the new CEO. The latest analyst rating for MGX stock is a Hold with a $2.00 price target, but challenges with profitability and cash flow have resulted in a low overall stock score.

    Tip Ranks·
    US
    MGX
    0.00%
    Tip Ranks·
    US
    MGX
    0.00%

    Metagenomi | 10-Q: FY2025 Q3 Revenue Beats Estimate at USD 8.659 M

    LB filings·
    US
    MGX
    0.00%
    LB filings·
    US
    MGX
    0.00%
    Posts
    View More

    Nvidia’s next-gen Rubin NVL 144 MGX servers are under development at Foxconn and will begin shipping in the 2nd half-2026, media report, citing unnamed industry sources. Foxconn began shipping the lat......